WASSC STANDS FOR ? WHOLE ANTIBODY SITE SPECIFIC CONJUGATE
“OUR UNIQUE TECHNOLOGY
Multisite Specific conjugation : Our new technology enables the production of homogeneous ADC. This means using conjugation aids to target pre-determined sites on the antibody, giving optimal, reproductible ADC production.
The selection of the conjugation site profoundly impacts the biochemical and pharmacodynamic characteristics of the antibody. This targeted approach simplifies the characterization process, resulting in reduced complexity and increased efficiency. Additionally, it leads to cost savings in ADC production, as it entails fewer constraints on machinery, equipment, and manpower requirements.
Our technology offers a notable advantage beyond optimizing the conjugation site. It allows for site-specific conjugation without the need for genetic engineering, resulting in improved drug-to-antibody ratios (DARs) while maintaining the integrity of the antibody. This approach ensures a more precise and effective ADC production, enhancing the overall performance of the therapeutic complex.
Built on basic protein principles, our technology applies to various applications that stretches far beyond ADCs.
See bellow the benefits
HOMOGENEOUS PRODUCTIONS
Achieve a greater reproducibility
READ MORE
LOWER MANUFACTURING COST
With the introduction of our advanced WASSC Site-directed Conjugation technology platform, it is not only possible to achieve greater homogeneity but also to produce more complex homogenous ADCs, leading to an enhanced and more consistent final product.
COMBINE MULTIPLE DRUGS
By creating a synergy, we improve efficiency
READ MORE
WE RESEARCH THE SYNERGY
Our research platform has unlocked the capability of conjugating multiple drugs onto a single ADC, creating a versatile and comprehensive treatment platform. The ability to combine various synergic drugs on ADCs elevates the importance of precise and targeted treatment delivery while lowering side-effects.
KEEPING THE ANTIBODY INTACT
Maintain structure and properties
READ MORE
THE WHOLE ANTIBODY
Through our cutting-edge science platform, we have achieved site-specific antibody conjugation without the need for gene engineering. By preserving the integrity of the antibody, we ensure that its biochemical properties remain unaltered, thereby avoiding issues caused by structural change and degradation.
DELIVERING ON TARGET CELLS
Precise delivery lowers side-effects
READ MORE
AVOID HARMING GOOD CELLS
With the aid of our state-of-the-art ADC research platforms, we have mastered the art of delivering treatments exclusively to cancer cells or other specified target cells. This targeted delivery approach maximizes treatment effectiveness while minimizing potential adverse effects in non-targeted regions.
IMMUNE SYSTEM'S HELPING OUT
The immune system is tagging along
READ MORE
RECOGNIZED BY THE BODY
WASSC's science is striving to educate the patient's immune system to recognize and attack pathogen agents and cancer itself. Our scientific department is developing tools and combination treatments to boost the efficiency of the immune system.
Keeping the whole antibody’s intact !
– wassc technologie
“WASSC'S platforms are the solution to optimize your bioactive molecules & solve your issues
#1 wassc's ACCELERATE
WASSC’S Accelerate the development of innovative treatment by offering a unique opportunity to produce the next generation of ADC and Vaccine by using its bioconjugation screening platform and drug/linker design platform.
#2 wassc's DEVELOP
WASSC’S Develop new delivery system based on simplest and tunable nanoemulsion system and hydrogel technologies useful for topic, oral and other administration mode.
#3 wassc's CREATE
WASSC’S Create a multidisciplinary team built with different expertise and experiences that allow us to approach science in a different way to obtain the most out of each project
